Kitov Pharma - volles Risiko - 500 Beiträge pro Seite
eröffnet am 06.02.17 22:44:25 von
neuester Beitrag 15.01.19 20:42:47 von
neuester Beitrag 15.01.19 20:42:47 von
Beiträge: 23
ID: 1.246.269
ID: 1.246.269
Aufrufe heute: 0
Gesamt: 3.116
Gesamt: 3.116
Aktive User: 0
ISIN: US49803V2060 · WKN: A2QA6T
4,1700
USD
+2,21 %
+0,0900 USD
Letzter Kurs 22.12.20 NYSE
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 51,75 | +91,67 | |
| 1,9000 | +59,66 | |
| 0,6000 | +57,48 | |
| 1,3500 | +29,82 | |
| 1,5700 | +25,60 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,3000 | -17,27 | |
| 3,0200 | -23,54 | |
| 2,8200 | -23,99 | |
| 5,2300 | -32,95 | |
| 9,6550 | -33,46 |
Feedback
Der CEO wurde heute wegen Betrugsverdacht verhört, aktuell 50% im Minus.
News bisher nur aus Israel:
https://translate.google.com/translate?sl=auto&tl=en&js=y&pr…
Kaufen wenn die Kanonen donnern: Habe mir mal eine Miniposition zu 1,50$ gegönnt, mal schauen was draus wird.
News bisher nur aus Israel:
https://translate.google.com/translate?sl=auto&tl=en&js=y&pr…
Kaufen wenn die Kanonen donnern: Habe mir mal eine Miniposition zu 1,50$ gegönnt, mal schauen was draus wird.
Antwort auf Beitrag Nr.: 54.254.471 von DWL33 am 06.02.17 22:44:25
Schnell rein, schnell raus zu 1,70$.
Zu halten bis hier Klarheit herrscht ist mir auch bei kleinem Einsatz doch zu riskant solange wir nicht deutlich unter Cash notieren...
Zu halten bis hier Klarheit herrscht ist mir auch bei kleinem Einsatz doch zu riskant solange wir nicht deutlich unter Cash notieren...
Antwort auf Beitrag Nr.: 54.254.735 von DWL33 am 06.02.17 23:39:20Wie hast Du da welche zu $1,50 bekommen? Sieht so aus, als wäre sie vom Handel ausgesetzt.... Au weia....
zum aktuellen Kurs gutes Chance / Risiko Verhältnis für die nächsten 3 Wochen, aktuell $1,34.
Trading Spotlight
Antwort auf Beitrag Nr.: 55.321.120 von DWL33 am 13.07.17 20:40:09Im Lauf der nächsten Woche wird das NDA filing erwartet, mal schauen ob man diesmal den Zeitplan hält. Mit Zulassung können wir locker eine mkap von 100-200 mit usd erreichen. Auch das Studien Ziel wurde mit höchster statistischer signifikanz deutlich erreicht. Von der Seite erstmal beste Chancen. Es stehen auch bald die Ergebnisse einer Zusatz Studie zum Einfluss auf die Nierenfunktion an, diese hat man durchgeführt um eine zuvor beobachtete Verbesserung zu belegen.
Grund für die noch immer extrem niedrige Bewertung ist verspieltes vertrauen beim nda Zeitplan, die letzte ke, Tendenz zur Selbsbereicherung des Managment. Es gibt ausserdem eine Untersuchung durch die ISA, welche zu Zweifeln an der Validität der klinischen Daten geführt hat. Unterm Strich ein 50-50 zock auf einen tenbagger in neun Monaten. Da es zudem eine mini Pommes Bude ist, ist eine Partnerschaft für Vertrieb mit Big Pharma fast sicher falls man nicht gleich übernommen wird.
http://3dcommunications.us/bio/paul-waymack-md-scd/
Paul Waymack, MD, ScD
Paul Waymack is a regulatory consultant, and previously worked as an FDA Medical reviewer and special consulting reviewer, responsible for assessing new drug applications and investigational drug applications.
https://www.bloomberg.com/research/stocks/private/person.asp…
Grund für die noch immer extrem niedrige Bewertung ist verspieltes vertrauen beim nda Zeitplan, die letzte ke, Tendenz zur Selbsbereicherung des Managment. Es gibt ausserdem eine Untersuchung durch die ISA, welche zu Zweifeln an der Validität der klinischen Daten geführt hat. Unterm Strich ein 50-50 zock auf einen tenbagger in neun Monaten. Da es zudem eine mini Pommes Bude ist, ist eine Partnerschaft für Vertrieb mit Big Pharma fast sicher falls man nicht gleich übernommen wird.
http://3dcommunications.us/bio/paul-waymack-md-scd/
Paul Waymack, MD, ScD
Paul Waymack is a regulatory consultant, and previously worked as an FDA Medical reviewer and special consulting reviewer, responsible for assessing new drug applications and investigational drug applications.
https://www.bloomberg.com/research/stocks/private/person.asp…
Expected Upcoming Milestones:
FDA filing of our NDA for KIT-302
Top-line results of our renal function clinical trial for KIT-302
Additional marketing agreements for the distribution of KIT-302
Pre-IND meeting with the FDA for NT-219
Bei der letzten KE hat fast der gesamte Vorstand zugeschlagen, man kann es als gutes Zeichen stehen auch wenn es zu solch niedrigen Kursen nicht die feine Art ist.
FDA filing of our NDA for KIT-302
Top-line results of our renal function clinical trial for KIT-302
Additional marketing agreements for the distribution of KIT-302
Pre-IND meeting with the FDA for NT-219
Bei der letzten KE hat fast der gesamte Vorstand zugeschlagen, man kann es als gutes Zeichen stehen auch wenn es zu solch niedrigen Kursen nicht die feine Art ist.
Es ist Zeit wieder einzusteigen!
Antwort auf Beitrag Nr.: 55.623.911 von DWL33 am 29.08.17 22:23:53Hier könnte es noch zu Verpartnerung, Übernahme oder guten Nachrichten bzgl. Einstellung der Ermittlung kommen. Kurse knapp über 2$ bieten sich zum Einstieg an.
Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis Pharmaceuticals
- Kitov to receive $3.5M milestone payments and 40% - 60% of net profit on sales of Consensi ™
- Coeptis to cover all CMC, sales, and marketing expenses
TEL AVIV, Israel, January 3, 2019- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. market. Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.
The agreement provides for total milestone payments from Coeptis to Kitov of $3.5 million, of which Kitov has already received the initial milestone upon execution of the agreement, and additional milestone payments are due upon completion of an agreed Chemistry, Manufacturing, Contol (CMC) plan and upon first commercial sales in the U.S. In addition, Kitov will be paid 40%-60% of Coeptis’ net profit on Consensi™ sales. The agreement is for a term of fifteen years and may be extended for additional two-year terms and includes customary provisions, as well as certain residual rights and obligations of the parties following termination.
Consensi™, under patent protection in the U.S. until 2030, is expected to be launched during 2019, and will be the only NSAID whose labeling indicates a reduction of blood pressure and consequent risk reduction of heart attack, stroke and death. For patients, Consensi™ treats two conditions simultaneously, thereby increasing convenience (one pill instead of two) and may offer lower co-pays. The therapy may contribute to improved patient compliance and improved patient health, thereby lowering overall health care costs.
The agreement with Coeptis is Kitov’s third licensing and distribution agreement as part of its worldwide commercialization plans for Consensi™. Kitov has previously signed licensing and distribution agreements for the drug in China and South Korea, and Kitov is currently evaluating additional commercialization agreements in major markets worldwide.
“This commercialization structure for Consensi™ is one that we believe optimizes Kitov’s near and long-term cash flows, enabling us to continue to develop and deliver additional innovative pharmaceuticals, while maximizing ROI for our shareholders. We are very pleased by the opportunity to work with Coeptis and its outstanding team of executives with strong track records in the pharmaceutical industry and look forward to Consensi™ creating better patient compliance and improved treatment for people living with osteoarthritis pain and hypertension,” Kitov’s CEO, Isaac Israel stated. “In the U.S., an estimated 44% of adults have both hypertension and osteoarthritis. Currently, these patients are not well served. We believe that successful commercialization of Consensi™ in the U.S. will be a transformational value-creating event for Kitov.”
David Mehalick, CEO of Coeptis, said, “Consensi™ will substantially improve treatment for patients living with two highly prevalent chronic conditions, delivering improved clinical outcomes and enhanced economics for healthcare providers. We anticipate launching Consensi™ in the second half of 2019 and expect to have it widely available to the millions of Americans who can benefit from this combination treatment.”
About Consensi™
Full US Prescribing Information, including BOXED WARNING and Medication Guide is available at: www.consensi.com.
Indications and Usage:
Consensi™ is a combination of amlodipine besylate, a calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarctions.
Limitations of Use:
Consensi™ is only available in a celecoxib strength of 200 mg and is only to be taken once daily.
Important Safety Information (ISI) for Consensi™
The following ISI is based on the Highlights section of the U.S. Prescribing Information for Consensi™. Please consult the full Prescribing Information for all of the labelled safety information for Consensi™.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.
Consensi™ is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.
Consensi™ is contraindicated in patients with a known hypersensitivity to amlodipine, celecoxib or any of its inactive ingredients.
Consensi™ is contraindicated in patients with a known history of asthma, urticaria or other allergic-type reactions after taking aspirin or other NSAIDs and in the setting of CABG surgery.
Consensi™ is contraindicated in patients with known demonstrated allergic-type reactions to sulfonamides.
Significant warnings and precautions related to Consensi™ include the following:
Patients should be warned about the potential signs and symptoms of hepatotoxicity and hepatic failure. Physicians should discontinue Consensi™ if abnormal liver tests persist or worsen, or if clinical signs and symptoms of liver disease develop.
Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Physicians should carefully monitor blood pressure.
Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis.
Worsening angina and acute myocardial infarction, particularly in patients with severe obstructive coronary artery disease, is possible.
Physicians should avoid use of Consensi™ in patients with severe heart failure.
Physicians should monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia, and avoid the use of Consensi™ in patients with advanced renal disease.
Patients should seek emergency help if an anaphylactic reaction occurs.
Consensi™ is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).
Physicians should discontinue Consensi™ at the first appearance of skin rash or other signs of hypersensitivity.
NSAIDs such as Consensi™ can cause premature Closure of Fetal Ductus Arteriosus.
Avoid use in pregnant women starting at 30 weeks of gestation.
Physicians should monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia.
Consensi™ is not recommended in patients with moderate or severe hepatic impairment or severe renal insufficiency.
Consensi™ is not recommended in Poor Metabolizers of CYP2C9 Substrates.
To report SUSPECTED ADVERSE REACTIONS, contact Kitov Pharma at 1-800-651-6606 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
About Coeptis Pharmaceuticals
Coeptis Pharmaceuticals, Inc. is a privately held biopharmaceutical company engaged in the acquisition, development and commercialization of branded and generic pharmaceutical products. The company owns an expansive portfolio of biotechnology assets encompassing a wide array of treatments including advanced innovations for cellular therapies such as CAR-T and CAR-NK with a focus on cancer, and various small molecule therapies for neurological based indications. Headquartered near Pittsburgh, PA, the company holds a robust pipeline of products in various stages of development and commercialization. http://www.coeptispharma.com (Information provided by Coeptis.)
About Kitov Pharma
Kitov Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is an innovative pharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare and business professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, Consensi™, intended to treat osteoarthritis pain and hypertension simultaneously, was approved by the FDA for marketing in the U.S. In addition, Kitov’s NT219, is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives. For more information on Kitov, the content of which is not part of this press release, please visit http://www.kitovpharma.com.
Quelle: SEC
- Kitov to receive $3.5M milestone payments and 40% - 60% of net profit on sales of Consensi ™
- Coeptis to cover all CMC, sales, and marketing expenses
TEL AVIV, Israel, January 3, 2019- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. market. Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.
The agreement provides for total milestone payments from Coeptis to Kitov of $3.5 million, of which Kitov has already received the initial milestone upon execution of the agreement, and additional milestone payments are due upon completion of an agreed Chemistry, Manufacturing, Contol (CMC) plan and upon first commercial sales in the U.S. In addition, Kitov will be paid 40%-60% of Coeptis’ net profit on Consensi™ sales. The agreement is for a term of fifteen years and may be extended for additional two-year terms and includes customary provisions, as well as certain residual rights and obligations of the parties following termination.
Consensi™, under patent protection in the U.S. until 2030, is expected to be launched during 2019, and will be the only NSAID whose labeling indicates a reduction of blood pressure and consequent risk reduction of heart attack, stroke and death. For patients, Consensi™ treats two conditions simultaneously, thereby increasing convenience (one pill instead of two) and may offer lower co-pays. The therapy may contribute to improved patient compliance and improved patient health, thereby lowering overall health care costs.
The agreement with Coeptis is Kitov’s third licensing and distribution agreement as part of its worldwide commercialization plans for Consensi™. Kitov has previously signed licensing and distribution agreements for the drug in China and South Korea, and Kitov is currently evaluating additional commercialization agreements in major markets worldwide.
“This commercialization structure for Consensi™ is one that we believe optimizes Kitov’s near and long-term cash flows, enabling us to continue to develop and deliver additional innovative pharmaceuticals, while maximizing ROI for our shareholders. We are very pleased by the opportunity to work with Coeptis and its outstanding team of executives with strong track records in the pharmaceutical industry and look forward to Consensi™ creating better patient compliance and improved treatment for people living with osteoarthritis pain and hypertension,” Kitov’s CEO, Isaac Israel stated. “In the U.S., an estimated 44% of adults have both hypertension and osteoarthritis. Currently, these patients are not well served. We believe that successful commercialization of Consensi™ in the U.S. will be a transformational value-creating event for Kitov.”
David Mehalick, CEO of Coeptis, said, “Consensi™ will substantially improve treatment for patients living with two highly prevalent chronic conditions, delivering improved clinical outcomes and enhanced economics for healthcare providers. We anticipate launching Consensi™ in the second half of 2019 and expect to have it widely available to the millions of Americans who can benefit from this combination treatment.”
About Consensi™
Full US Prescribing Information, including BOXED WARNING and Medication Guide is available at: www.consensi.com.
Indications and Usage:
Consensi™ is a combination of amlodipine besylate, a calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarctions.
Limitations of Use:
Consensi™ is only available in a celecoxib strength of 200 mg and is only to be taken once daily.
Important Safety Information (ISI) for Consensi™
The following ISI is based on the Highlights section of the U.S. Prescribing Information for Consensi™. Please consult the full Prescribing Information for all of the labelled safety information for Consensi™.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.
Consensi™ is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.
Consensi™ is contraindicated in patients with a known hypersensitivity to amlodipine, celecoxib or any of its inactive ingredients.
Consensi™ is contraindicated in patients with a known history of asthma, urticaria or other allergic-type reactions after taking aspirin or other NSAIDs and in the setting of CABG surgery.
Consensi™ is contraindicated in patients with known demonstrated allergic-type reactions to sulfonamides.
Significant warnings and precautions related to Consensi™ include the following:
Patients should be warned about the potential signs and symptoms of hepatotoxicity and hepatic failure. Physicians should discontinue Consensi™ if abnormal liver tests persist or worsen, or if clinical signs and symptoms of liver disease develop.
Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Physicians should carefully monitor blood pressure.
Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis.
Worsening angina and acute myocardial infarction, particularly in patients with severe obstructive coronary artery disease, is possible.
Physicians should avoid use of Consensi™ in patients with severe heart failure.
Physicians should monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia, and avoid the use of Consensi™ in patients with advanced renal disease.
Patients should seek emergency help if an anaphylactic reaction occurs.
Consensi™ is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).
Physicians should discontinue Consensi™ at the first appearance of skin rash or other signs of hypersensitivity.
NSAIDs such as Consensi™ can cause premature Closure of Fetal Ductus Arteriosus.
Avoid use in pregnant women starting at 30 weeks of gestation.
Physicians should monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia.
Consensi™ is not recommended in patients with moderate or severe hepatic impairment or severe renal insufficiency.
Consensi™ is not recommended in Poor Metabolizers of CYP2C9 Substrates.
To report SUSPECTED ADVERSE REACTIONS, contact Kitov Pharma at 1-800-651-6606 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
About Coeptis Pharmaceuticals
Coeptis Pharmaceuticals, Inc. is a privately held biopharmaceutical company engaged in the acquisition, development and commercialization of branded and generic pharmaceutical products. The company owns an expansive portfolio of biotechnology assets encompassing a wide array of treatments including advanced innovations for cellular therapies such as CAR-T and CAR-NK with a focus on cancer, and various small molecule therapies for neurological based indications. Headquartered near Pittsburgh, PA, the company holds a robust pipeline of products in various stages of development and commercialization. http://www.coeptispharma.com (Information provided by Coeptis.)
About Kitov Pharma
Kitov Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is an innovative pharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare and business professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, Consensi™, intended to treat osteoarthritis pain and hypertension simultaneously, was approved by the FDA for marketing in the U.S. In addition, Kitov’s NT219, is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives. For more information on Kitov, the content of which is not part of this press release, please visit http://www.kitovpharma.com.
Quelle: SEC
Antwort auf Beitrag Nr.: 59.550.055 von techinvestor69 am 03.01.19 13:42:40Falls Kitov von euch geordert wird, welche Börse eignet sich am besten!
Danke im voraus.
Th.
Danke im voraus.
Th.
Nasdaq ...
Antwort auf Beitrag Nr.: 59.574.485 von techinvestor69 am 07.01.19 13:38:24Nochmals danke.
Wie siehst Du die Entwicklung der nächsten 1-3 Monate?
Wie siehst Du die Entwicklung der nächsten 1-3 Monate?
2,50-3,00 USD, gerne auch mehr
Bin hier auch noch mit ein kleinen Position dabei.
Falls sich Consensi gut verkauft, ist Kitov sowas von unterbewertet...
Falls sich Consensi gut verkauft, ist Kitov sowas von unterbewertet...
Bis Consensi mal richtig anrollt, werden Monate vergehen.
Aber das Produkt NT219, wenn es mal zur Reife gelangt, würde alles in den Schatten stellen. Man rechnet alleine für die Forschung und klinischen Phasen auf mehr als 2 Milliarden US Dollar. Von den Erlösen von Consensi ist NT219 nicht zu bezahlen. Man sucht einen Big Pharma.
Aber das Produkt NT219, wenn es mal zur Reife gelangt, würde alles in den Schatten stellen. Man rechnet alleine für die Forschung und klinischen Phasen auf mehr als 2 Milliarden US Dollar. Von den Erlösen von Consensi ist NT219 nicht zu bezahlen. Man sucht einen Big Pharma.
Näher in der Materie drin oder warum so angetan von NT219? 😉
Mal Berichte über NT219 lesen. Kommt sehr gut rüber.
Respekt treehunter 😳🙌
Ich hoffe, du hast rechtzeitig investiert?!
Antwort auf Beitrag Nr.: 59.637.287 von Stoxtrayder am 15.01.19 17:53:11Hier noch die Meldung zum Anstieg
https://finance.yahoo.com/news/data-kitov-nt219-demonstrates…
Klingt schon gut, und die Marktkapitalisierung ist nach wie vor ein Witz. Kann was werden...
https://finance.yahoo.com/news/data-kitov-nt219-demonstrates…
Klingt schon gut, und die Marktkapitalisierung ist nach wie vor ein Witz. Kann was werden...
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,29 | |
| +5,01 | |
| -2,00 | |
| -3,25 | |
| 0,00 | |
| -0,37 | |
| -0,51 | |
| +2,17 | |
| -1,31 | |
| +2,50 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 196 | ||
| 192 | ||
| 72 | ||
| 32 | ||
| 32 | ||
| 29 | ||
| 28 | ||
| 28 | ||
| 27 |
